247 related articles for article (PubMed ID: 27267105)
1. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Siegel DS; Weisel KC; Dimopoulos MA; Baz R; Richardson P; Delforge M; Song KW; San Miguel JF; Moreau P; Goldschmidt H; Cavo M; Jagannath S; Yu X; Hong K; Sternas L; Zaki M; Palumbo A
Leuk Lymphoma; 2016 Dec; 57(12):2833-2838. PubMed ID: 27267105
[TBL] [Abstract][Full Text] [Related]
2. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Mushtaq A; Iftikhar A; Hassan H; Lakhani M; Sagar F; Kamal A; Zahid U; Ali Z; Razzaq F; Zar MA; Hassan SF; Safdar A; Raychaudhuri S; Anwer F
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):447-461. PubMed ID: 31060991
[TBL] [Abstract][Full Text] [Related]
7. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Dimopoulos M; Alegre A; Stadtmauer EA; Goldschmidt H; Zonder JA; de Castro CM; Masliak Z; Reece D; Olesnyckyj M; Yu Z; Weber DM
Cancer; 2010 Aug; 116(16):3807-14. PubMed ID: 20564094
[TBL] [Abstract][Full Text] [Related]
10. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Moreau P; Weisel KC; Song KW; Gibson CJ; Saunders O; Sternas LA; Hong K; Zaki MH; Dimopoulos MA
Leuk Lymphoma; 2016 Dec; 57(12):2839-2847. PubMed ID: 27173785
[TBL] [Abstract][Full Text] [Related]
11. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC
Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329
[TBL] [Abstract][Full Text] [Related]
13. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Maciocia N; Melville A; Cheesman S; Sharpley F; Ramasamy K; Streetly M; Jenner M; Benjamin R; Schey S; Maciocia P; Popat R; D'sa S; Rismani A; Cerner A; Yong K; Rabin N
Br J Haematol; 2017 Mar; 176(6):908-917. PubMed ID: 28211054
[TBL] [Abstract][Full Text] [Related]
14. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Dimopoulos MA; Leleu X; Moreau P; Richardson PG; Liberati AM; Harrison SJ; Miles Prince H; Ocio EM; Assadourian S; Campana F; Malinge L; Sémiond D; van de Velde H; Yong K
Leukemia; 2021 Feb; 35(2):562-572. PubMed ID: 32444867
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Cohen A; Spektor TM; Stampleman L; Bessudo A; Rosen PJ; Klein LM; Woliver T; Flam M; Eshaghian S; Nassir Y; Maluso T; Swift RA; Vescio R; Berenson JR
Br J Haematol; 2018 Jan; 180(1):60-70. PubMed ID: 29164606
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
[TBL] [Abstract][Full Text] [Related]
18. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
20. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Moreau P; Dimopoulos MA; Richardson PG; Siegel DS; Cavo M; Corradini P; Weisel K; Delforge M; O'Gorman P; Song K; Chen C; Bahlis N; Oriol A; Hansson M; Kaiser M; Anttila P; Raymakers R; Joao C; Cook G; Sternas L; Biyukov T; Slaughter A; Hong K; Herring J; Yu X; Zaki M; San-Miguel J
Eur J Haematol; 2017 Sep; 99(3):199-206. PubMed ID: 28504846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
